



# Arrhythmia and metabolism

**Danielle Feuvray**  
UMR CNRS 8078 & Université Paris-Sud XI, France

Correspondence: Professor Danielle Feuvray, CNRS UMR 8078 & Université Paris-Sud XI,  
Marie Lannelongue Hospital, 92350 Le Plessis Robinson, France.  
E-mail: danielle.feuvray@ibaic.u-psud.fr

The observation that plasma free fatty acid concentrations are increased during and immediately after myocardial infarction was made several decades ago [1]. Clinical observations showed that plasma free fatty acid concentrations greater than those that could bind to the two primary affinity-binding sites on albumin were associated with an increase in the incidence of ventricular arrhythmias during myocardial infarction [2]. Subsequently, it was proposed that certain arrhythmias have a metabolic basis [3]. The oxygen-wasting effects of increased provision of free fatty acids to the acutely ischemic myocardium were found to be augmented by impairment of the uptake or utilization of glucose [4]. These early findings led to the views that provision of glucose is "good" [5] and that the presence of increased circulating free fatty acid concentrations is "bad" [3] for the ischemic myocardium.

During ischemia,  $\beta$ -oxidation of long-chain fatty acids in mitochondria is inhibited and there is an intracellular accumulation of metabolites such as long-chain acyl carnitine and acyl coenzyme A. The metabolites that accumulate during ischemia-reperfusion may, indirectly, lead to ionic disturbances; in particular, they may alter both sodium and calcium homeostasis and contribute to electrical dysfunction. Increases in intracellular sodium ( $\text{Na}^+_i$ ), which have been demonstrated during ischemia-reperfusion [6], may indeed have functional and proarrhythmogenic consequences [7], because increases in  $\text{Na}^+_i$  in turn generate  $\text{Ca}^{2+}$  loading via reverse  $\text{Na}^+-\text{Ca}^{2+}$  exchange. Interestingly, it has been shown that trimetazidine, which inhibits fatty acid oxidation in the heart [8], also significantly reduces the increase in  $\text{Na}^+_i$  during ischemia and early reperfusion [6]. The most plausible underlying mechanisms for the gain in  $\text{Na}^+_i$  during ischemia are a decrease in  $\text{Na}^+$  extrusion via  $\text{Na}^+/\text{K}^+$ -ATPase or an influx of  $\text{Na}^+$  via  $\text{Na}^+-\text{H}^+$  exchange and the voltage-

gated  $\text{Na}^+$  channel, or both.  $\text{Na}^+-\text{H}^+$  exchange activity may be rapidly inhibited by extracellular acidosis during total ischemia, which suggests that voltage-gated  $\text{Na}^+$  channels may have a significant role as mediators of ischemic  $\text{Na}^+$  loading [9]. A large proportion of these channels become rapidly non-recruitable in ischemic tissues after resting membrane potential depolarization, and action potentials initially shorten and subsequently cease with exhaustion of cellular ATP.  $\text{Na}^+$  influx continues, however, through non-inactivated voltage-gated sodium channels, giving rise to persistent window currents [10,11]. Moreover, the slowly inactivating component of the  $\text{Na}^+$  current also increases substantially during ischemia, amplifying  $\text{Na}^+$  influx [11,12]. In this context, it has been shown that long-chain acyl carnitine, which accumulates in the cell membrane during ischemia, markedly increases the slowly inactivating component of the  $\text{Na}^+$  current [12]. Experimental data also indicate that acyl carnitine, like ouabain, produces a reversible inhibition of the  $\text{Na}^+/\text{K}^+$  pump current [13] and thereby a decrease in  $\text{Na}^+$  extrusion. Therefore, specific myocardial metabolic modulation such as with trimetazidine, which limits the accumulation of long-chain acyl carnitine during ischemia [14], may well limit the increase in  $\text{Na}^+_i$  via slowly inactivating the sodium channels and causing a relative increase in  $\text{Na}^+/\text{K}^+$  pump function. This would be particularly important in reducing ionic disturbances and the susceptibility of the myocardium to malignant arrhythmogenic events.

The experimental evidence summarized above probably represents only a few aspects of the fascinating machinery that may underlie the metabolic signals of arrhythmia. This issue of *Heart and Metabolism* will highlight the importance of metabolic disturbances, associated either with an imbalance of metabolic substrates or, as most recently reported, with genetic mutations that can alter the function of a key

regulatory enzyme of cardiac energy metabolism [15] and downstream effectors such as cardiac ion channels [16] and, possibly, other ion transporters. ■

## REFERENCES

1. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias [review]. *Lancet*. 1994;343:155–158.
2. Oliver MF, Kurien VA, Greenwood TW. Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. *Lancet*. 1968;i:710–714.
3. Kurien VA, Oliver MF. A metabolic cause of arrhythmias during acute myocardial hypoxia. *Lancet*. 1970;i:813–815.
4. De Leiris J, Lubbe WF, Opie LH. Effects of free fatty acid and glucose on enzyme release in experimental myocardial infarction. *Nature*. 1975;153:746–747.
5. Opie LH. Metabolic response during impending myocardial infarction: relevance of studies of glucose and fatty acid metabolism in animals. *Circulation*. 1972;45:483–490.
6. El Banani H, Bernard M, Baetz D, et al. Changes in intracellular sodium and pH during ischaemia–reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. *Cardiovasc Res*. 2000;47:688–696.
7. Pogwizd SM, Sipido KR, Verdonck F, Bers DM. Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis [review]. *Cardiovasc Res*. 2003;57:887–896.
8. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The anti-anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl CoA thiolase. *Circ Res*. 2000;86:580–588.
9. Pinet C, Le Grand B, John GW, Coulombe A. Thrombin facilitation of voltage-gated sodium channel activation in human cardiomyocytes. Implications for ischemic sodium loading. *Circulation*. 2002;106:2098–2103.
10. Coraboeuf E, Deroubaix E, Coulombe A. Effect of tetrodotoxin on action potentials of the conducting system in the dog heart. *Am J Physiol Heart Circ Physiol*. 1979;236:H561–H567.
11. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. *Circ Res*. 1992;71:1231–1241.
12. Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. *Am J Physiol Heart Circ Physiol*. 1994;266:H1034–H1046.
13. Tanaka M, Gilbert J, Pappano AJ. Inhibition of sodium pump by L-palmitoylcarnitine in single guinea-pig ventricular myocytes. *J Mol Cell Cardiol*. 1992;24:711–720.
14. El Banani H, Bernard M, Cozzone P, James F, Feuvray D. Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury. *Am J Cardiol*. 1998;82:25K–29K.
15. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. *J Clin Invest*. 2002;109:357–362.
16. Light PE. Familial Wolff–Parkinson–White Syndrome: a disease of glycogen storage or ion channel dysfunction? [review]. *J Cardiovasc Electrophysiol*. 2006;17 (suppl 1):S158–S161.